Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

09 May 2019

• By Joseph Haas and John Davis

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

More from Deals

More from Business